Cannabis Terpenes Matched Morphine in Mouse Pain Study, but Human Testing Is Still Needed
A 2023 study published in PAIN found that several terpenes associated with *Cannabis sativa* reduced pain-related behavior in mice with chemotherapy-induced neuropathy. At the doses tested, the compounds produced pain relief roughly comparable to morphine, while showing no evidence of reward in a commonly used behavioral test.
The findings are promising, but they are preliminary. The research was conducted in mice—not people—and it does not show that cannabis terpenes are ready to replace morphine or other pain medicines.
Researchers from the University of Arizona and the National Institute of Diabetes and Digestive and Kidney Diseases tested five terpenes commonly found in cannabis: alpha-humulene, beta-caryophyllene, beta-pinene, geraniol and linalool. Terpenes are aromatic plant compounds that contribute to the smell and flavor of cannabis, as well as many other plants.
The team used mouse models of chemotherapy-induced peripheral neuropathy, a form of nerve pain caused by some cancer treatments, and inflammation-related pain. The terpenes were compared with morphine and a synthetic cannabinoid. In the neuropathy model, all five compounds produced antinociceptive effects—reducing behavioral signs of pain—at levels broadly similar to those produced by morphine.
The researchers also tested lower doses of the terpenes in combination with morphine. Each terpene enhanced morphine’s pain-relieving effect in the experiments, suggesting that a combination approach might eventually allow lower opioid doses. However, the study did not establish that terpenes can prevent opioid addiction or make opioid treatment safe for human use.
The study included several tests designed to identify potentially undesirable effects. None of the terpenes produced conditioned place preference, a laboratory measure associated with reward and abuse liability. Geraniol and linalool also did not produce significant preference or aversion in the relevant tests. Alpha-humulene and beta-caryophyllene, however, produced place aversion under some conditions, indicating that the compounds may not have identical behavioral profiles.
The route of administration was another important limitation. The strongest effects were observed after injection. When the compounds were administered orally or by inhalation of vaporized, purified terpenes, their effects were substantially weaker or absent. That result raises questions about how much terpene would reach the relevant tissues in people and whether commercially available cannabis products would produce comparable effects.
Additional experiments pointed to adenosine A2A receptors in the spinal cord as part of the mechanism behind the pain relief. The researchers used a selective receptor antagonist and a spinal-cord-specific gene-silencing approach to reduce the terpenes’ effects. Laboratory binding and signaling experiments further suggested that the compounds may act on these receptors. These mechanistic findings remain preclinical and do not establish how terpenes would work in patients.
The results add to a broader research effort examining whether cannabis compounds other than THC and CBD contribute to pain relief. The concept is sometimes described as the “entourage effect,” in which multiple plant compounds interact to alter therapeutic effects. Evidence for such interactions is still developing, and studies of cannabis-based treatments in humans have generally found modest benefits alongside potential adverse effects. The National Center for Complementary and Integrative Health’s overview of cannabis and cannabinoids describes the current clinical evidence and its limitations.
For now, the University of Arizona findings are best viewed as a lead for drug discovery rather than proof of a new pain treatment. Human studies will be needed to determine whether specific terpenes can relieve neuropathic pain, what doses are effective, how they should be delivered, and whether their safety advantages over opioids persist outside animal models. The university’s report on the research likewise emphasizes the need to address these translational challenges before clinical use can be considered.
